Bank of Montreal
NRSN icon

Bank of Montreal’s NeuroSense Therapeutics NRSN Stock Holding History

Bank of Montreal’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,000
Closed -$65K – 4322
2022
Q1 		$65K Buy
+10,000
New +$23.8K ﹤0.01% 3746

Other funds holding NRSN

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

Bank of Montreal's NRSN Position: Q2 2022 in Review

Bank of Montreal sold out of NeuroSense Therapeutics (NRSN) in Q2 2022, closing a stake of 10,000 shares — an estimated $65K sold.

Bank of Montreal first reported a position in NRSN in Q1 2022 and held it in 1 quarter. The position peaked at $65K in Q1 2022. 7 funds tracked by Wall St. Rank hold NRSN as of Q2 2022.

  • Bank of Montreal reported no remaining NeuroSense Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bank of Montreal sold 10,000 NeuroSense Therapeutics shares in Q2 2022, an estimated $65K.
  • Bank of Montreal first reported a position in NeuroSense Therapeutics in Q1 2022 and held it in 1 quarter.
  • Bank of Montreal's NeuroSense Therapeutics position peaked at $65K in Q1 2022.
  • 7 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2022.

Based on Bank of Montreal's 13F filing for Q2 2022, filed 11 Aug 2022.